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Nanotechnology oﬀers an alternative to conventional treatment options by enabling diﬀerent drug delivery and controlled-release
delivery strategies. Liposomes being especially biodegradable and in most cases essentially nontoxic oﬀer a versatile platform for
several diﬀerent delivery approaches that can potentially enhance the delivery and targeting of therapies to tumors. Liposomes
penetrate tumors spontaneously as a result of fenestrated blood vessels within tumors, leading to known enhanced permeability
andsubsequentdrugretentioneﬀects.Inaddition,liposomescanbeusedtocarryradioactivemoieties,suchasradiotracers,which
can be bound at multiple locations within liposomes, making them attractive carriers for molecular imaging applications. Phage
display is a technique that can deliver various high-aﬃnity and selectivity peptides to diﬀerent targets. In this study, gelatinase-
binding peptides, found by phage display, were attached to liposomes by covalent peptide-PEG-PE anchor creating a targeted drug
delivery vehicle. Gelatinases as extracellular targets for tumor targeting oﬀer a viable alternative for tumor targeting. Our ﬁndings
show that targeted drug delivery is more eﬃcient than non-targeted drug delivery.
1.Introduction
Liposomal nanotechnology provides a versatile platform for
exploring several approaches that can potentially enhance
the delivery and targeting of therapies to tumors. As a
biodegradable and essentially nontoxic platform, liposomes
can be used to encapsulate both hydrophilic and hydropho-
bic materials and be utilized as drug carriers in drug delivery
systems (DDSs). In addition, liposomes can be used to
carry radioactive moieties, such as radiotracers, which can
be bound at multiple locations within liposomes, making
them attractive carriers for molecular imaging applications.
In this study, gelatinase-binding peptides were attached
to liposomes for synthesizing a targeted drug delivery
vehicle.
Foractivetargetingordrugdeliveryapplications orboth,
intraliposomal encapsylation of multiple targeting agents or
therapies can be (i) to the lipid bilayer, which can bind
hydrophobic conjugates; (ii) to hydrated compartments for
water-soluble components; (iii) by covalent binding directly
or by utilizing spacer to the outer lipid leaﬂet [1]. Delivery
of these nanoformulations to the reticuloendothelial system
(RES) is readily achieved since, given their larger size, the
RES traps most conventional liposomes that are not shielded
by polyethylene glycol chains (PEGs) or other similar steric
water carrying substance. RES uptake can be increased by
altering particle surface chemistry and charge, for instance,
by adding positively charged lipids or biologically activating
proteins or sugars on the surface of the liposomes. For
purposes of agent delivery to target organs other than the2 Journal of Drug Delivery
RES, long-circulating liposomes have been developed by
modifying the liposomal surface [2]. Determination of the
in vivo biodistribution and targeting kinetics of liposome-
encapsulated drugs is required for the assessment of drug
bioavailability.
The most commonly used nanoformulated drug is
Caelyx/Doxil, a liposomal doxorubicin product. It has nearly
supplanted doxorubicin in the therapy of ovarian cancer,
breast cancer, and Kaposi’s sarcoma. It diﬀers from the
former generation liposomal delivery systems, as the outer
surface of Caelyx/Doxil is coated with PEG chains that
protect the liposomes from being opsonized by components
of the immune system in the circulation. These stealth-type
liposomes have longer circulation half-times than those for
uncoated liposomes. In addition, they are safer than the
nativedrugsthemselves(e.g.,Caelyx/Doxilisnotcardiotoxic,
a major concern for native doxorubicin delivery).
For cancer-based applications, peptides that can selec-
tively detect and target metastatic disease and tumor inva-
sive potential may oﬀer critical prognostic information.
Metastatic invasion is promoted by the attachment of tumor
cells to the extracellular matrix, the degradation of matrix
components by tumor-associated proteases, and the cellular
movementintotheareamodiﬁedbyproteaseactivity.Matrix
metalloproteases (MMPs) represent a family of enzymes
capable of degrading the basement membrane and extracel-
lular matrix (ECM), thus contributing to tissue remodeling
and cell migration [3–5]. This family of enzymes can cleave
ECM proteins, as well as alter the integrity of basement
membranes that serve as barriers to cell movement. This is
normally a tightly regulated process, with the presence of
activated metalloproteinases occurring only under speciﬁc
conditions.
MMPs may be divided into subgroups, one comprised of
typeIVcollagenases(gelatinases)suchasMMP-2andMMP-
9, which play major roles in tumor growth, angiogenesis,
and metastatic disease. These gelatinases degrade type IV
collagen (and its breakdown product, gelatin) and comprise
the primary structural component of the ECM, enabling
tumor cells to gain access to the rest of the body. Overex-
pression and/or prognostic signiﬁcance of gelatinases have
been examined in a range of cancer types, including ovarian
cancer [6–9], endometrial and cervical cancer [10, 11], and
breast cancer [12, 13]. High expression levels of gelatinases
in breast and ovarian cancers, for instance, are known to be
associated with unfavorable prognoses.
In this study, binding peptides (BPs) extracted from
MMP-9 were attached to liposomes for synthesizing a
targeted drug delivery vehicle. Downregulation of MMP-
9 is known to exert inhibitory eﬀects on endothelial cell
migration and tube formation [14]. Intriguingly MMP-2 has
been shown to dock on tumor cell-surface integrins, which
makes gelatinases even more interesting as a target [15].
Adenoviral-mediated MMP-9 downregulation was shown
to retard endothelial cell migration in cell wounding and
spheroid migration assays, resulting in reduced capillary-
like tube formation [16]. MMP-2- or MMP-9-deﬁcient mice
were found to exhibit abnormal angiogenic properties [17].
Further, in human gliomas, immunohistochemical ﬁndings
suggested that neoplastic and endothelial cells expressing
MMP-9proteinmaybeassociatedwithtumoralangiogenesis
[18].
One of the ﬁrst known speciﬁc gelatinase inhibitors, a
cyclic MMP-9-binding peptide identiﬁed by random phage
display libraries (i.e., CTTHWGFTLC peptide later CTT1),
has previously been shown to have high aﬃnity not only
to MMP-9, but also to MMP-2 [19]. The peptide actively
inhibits endothelial and tumor cell migration in vitro and
tumor progression in in vivo murine models [19]. Specif-
ically, CTT-displaying phages block the formation of new
blood vessels, resulting in tumor size reductions and pro-
longedoverallsurvival.Theseﬁndingshighlightthepotential
of CTT peptide for targeting chemotherapeutics or other
imaging probes to the tumor neovasculature. CTT-peptide
has been used for liposomal drug delivery in vitro and in vivo
[20, 21] and has been shown to be eﬀective in improving
selective localization of chemotherapies such as doxorubicin
in human tumor cells. In this work we modiﬁed a CTT
peptide with a peptide linker that bears a tyrosine moiety for
iodination procedures and attached several additional amino
acids (GRENYHG) to enhance freedom of peptide binding
in order to create GRENYHGCTTHWGFTLC-peptide (i.e.,
CTT2-peptide) (Figure 1). The synthesis of CTT2-peptide
enabled us to retain bioactivity that would otherwise not be
present if CTT peptide itself was directly linked to lipids or
PEG spacers. This is the ﬁrst study, to our knowledge, that
has utilized a peptide derived from a synthetic phage display
library for constructing a more selective liposomal delivery
system for targeting extracellular target molecules.
We initially present the synthesis of PEG-PE-CTT2
peptide-bound micelles and liposomes. The feasibility of uti-
lizing micellar and liposomal nanoformulations as therapeu-
tic delivery vehicles to achieve eﬃcacy in ovarian carcinoma
models was explored by attaching the radioiodinated CTT
peptide tracer, 125I-CTT2 peptide, to these platforms and
loading them with doxorubicin, an inherently ﬂuorescent
chemotherapeutic agent. Biodistribution studies of both
targeted nanoformulations were performed in normal and
immunosuppressed subcutaneous human xenograft models
using the CTT2-peptide.
2.MaterialsandMethods
Reagents. All reagents, unless stated otherwise, were
obtained from Sigma-Aldrich (St Louis, Missouri, USA)
and culture media from Gibco Life Technologies (Paisley,
Scotland). PEG-PE-NHS was from Avanti Polar Lipids Inc.
(Alabama, USA) as all the other lipids used in this study.
2.1. Synthesis of Peptides. Peptides were synthesized on an
Applied Biosystems 433A (Foster City, CA, USA) automatic
synthesizer using Fmoc-chemistry. For disulﬁde generation,
peptides were dissolved at 1mg/ml in 0.05M ammonium
acetate (pH 8) and mixed with H2O2 for 40min at room
temperature so that 0.5ml of 3% H2O2 was added per
100mgpeptide.Thepeptideswerepuriﬁedbyreversedphase
HPLC, and the molecular weight was identiﬁed by mass
spectrometry analysis.Journal of Drug Delivery 3
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Figure 1: Chemical structure of 125I-CTT2-peptide. CTT2-peptide is a 17-amino acid peptide with a disulphide bridge between the two
cysteines. The amino terminal end of the peptide is amidated to increase its stability. Upon iodination, peptide labeling occurs on the
aromatic ring of the tyrosine amino acid.
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Figure 2: Chemical structure of CTT2-PEG3400-DSPE. CTT2-PEG3400-DSPE was synthesized by coupling CTT2-peptide to PEG3400-
DSPE, followed by puriﬁcation of the reaction product from the initial mixture.
2.2. Synthesis of DSPE-PEG3400-CTT2. Coupling bioactive
peptides to PEGylated lipids can alter the pharmacokinetics
and dynamics of these peptides. For pharmaceutical for-
mulation purposes, CTT2-peptide (Figure 1)w a sc o v a l e n t l y
attached to the PEG phospholipid (Figure 2).
In this procedure, the peptide called CTT2 (cyclo-
GRENYHGCTTHWGFTLC- NH2) was covalently attached
to PEG phospholipids through the chemical reaction
betweentheterminalamineofthepeptideandthefunctional
NHS (hydroxysuccinimidyl) group at the end of the PEG
phospholipid polymer chain. The reaction between the
terminal amine and the active succinimidyl ester of the PEG
carboxylic acid produced a stable amide linkage. Diﬀerent
molarratiosofthepeptideandthePEGphospholipid,aswell
as the reaction times, were varied to optimize the coupling
reaction. Up to several hundred CTT2-PEG-lipid molecules
can be attached to the surface of each liposome.
CTT2 peptide (8.8mg) and DSPE-PEG3400-NHS
(100mg) were dissolved in 2 milliliters (ml) dimethyl-form-
amide. CTT2 peptide solution (500μl) was mixed with
600μl of DSPE-PEG3400-NHS solution and incubated for
21 hours (hrs). Samples were then precipitated by addition
of diethylether and centrifuged (13200rpm for 10min). The
supernatant was decanted and the solid residue was stored at
−70◦C.
For all studies, samples were reconstituted by adding
100μlmethanoland25μlof1Msodiumhydroxide,followed
by 250μl of 1% TFA in water after two hours. Analysis of
these samples was performed after centrifugation (4200rpm
20min) using a C-18 RP-HPLC by initially precipitating the
puriﬁed product with excess diethylether. The solid residues
weredissolvedin1500μlmethanolandanalyzedbythinlayer
chromatography (TLC). Reaction yields for CTT2 peptide-
DSPE-PEG3400-NHS coupling averaged 6.0mg.
2.3. Preparation of Liposomes
2.3.1. CTT2-Micelles. Monomers or CTT2-PEG3400-DSPE
(i.e., CTT2-PEG-lipid) spontaneously formed micelles ∼
14nm in diameter (i.e., CTT2-micelles) in aqueous solution,
with DSPE lipid chains forming the hydrophobic core and
PEGylated CTT2-peptide forming the hydrophilic surface
of the micelle. CTT2-micelles were covalently labeled with
radioiodine, I-125 (125I, half-life = 13hrs), to determine
time-varying tissue distributions and tumor uptakes. Radio-
chemical purity of ∼90% was achieved.4 Journal of Drug Delivery
Table 1: Tumor uptake of various liposomal constructs.
Caelyx CTT2-SL liposome
Targeted formulation No Yes
Concentration-targeted
formulation —0 . 2 %
Analyte Doxorubicin Doxorubicin
Time point (hours) 6 6
Tumor uptake (%
ID/gram) 8.1% 19.0%
Table 2
Lipid percent (%)
CTT2-SL liposome
DSPE-mPEG2000 3.2mg/ml 1.2mM 5.5%
HSPC 9.6mg/ml 12.2mM 56.2%
Cholesterol 3.2mg/ml 8.2mM 38.1%
CTT2-PEG-lipid 0.2mg/ml 0.04mM 0.2%
Total lipids 16.2mg/ml 21.6mM 100.00%
Caelyx
DSPE-mPEG2000 3.2mg/ml 1.2mM 5.5%
HSPC 9.6mg/ml 12.2mM 56.3%
Cholesterol 3.2mg/ml 8.2mM 38.2%
Total lipids 16.0mg/ml 21.6mM 100.0%
2.3.2. CTT2-SL Liposomes. CTT-2-peptide-targeted lipo-
somes were synthesized either by incorporating CTT2-PEG-
lipid onto the surface of commercially available liposomes or
by combining CTT2-micelles with liposomal formulations.
Prior studies have shown that incubation of certain lipids
withliposomescanresultinintraliposomalinclusionofthese
lipids as a consequence of micellar-liposomal fusion [23,
24]. This spontaneous process, occurring when lipid con-
centrations exceed critical micellar concentrations (CMC),
has been used as a postinsertion technique with preformed
liposomestoproduceimmunoliposomes [25]andliposomes
coated with peptides or oligosaccharides [26, 27]. CTT2-
micelles were combined with the commercially available
nanoformulated drug, Caelyx (PEGylated liposomal doxoru-
bicin HCl), to form CTT2-peptide-targeted Caelyx (CTT2-
SL liposome). This method provides a CTT2-PEG-lipid
content of ∼0.2% of all lipids on the resulting liposome sur-
face; CTT2-peptide-lipid concentrations are essentially the
maximum achievable concentrations using CTT2-micelle
methodologies as Caelyx liposomes are PEGylated. The lipid
componentsofCTT2-SLliposomeandCaelyxthatwereused
for these studies are listed in Table 2.
CTT2-SL liposomes were made by pipetting the above-
mentioned lipid mixture except the CTT2-PEG-lipid, to a
round bottomed ﬂask, dried under nitrogen and lyophilized
for 2h to remove trace amounts of chloroform. Doxorubicin
liposomes were prepared by using standard pH gradient
technique [1].
To synthesize CTT2-PEG-3400-DSPE Caelyx/doxil-lipo-
somes, CTT2-PEG-DSPE (1mg) was suspended in 400μl
of buﬀer (100mM histidine, 55mM sucrose, pH 6.5), and
100μl of this CTT2-PEG-DSPE micelle suspension was
added to 1ml Doxil/Caelyx solution or internally prepared
similar to doxil-liposomes (Ortho Biotech). In vivo murine
studies were performed after incubating the mixture for
30min at 60◦C.
The incorporation eﬃciency, the percentage of total
activity contained in the liposome fractions, was measured
by using radioisotope-labeled peptide and gel ﬁltration to
separate the unreacted micelle from the liposome; optimal
reaction conditions were found to be 60◦Ca t3 0m i n( n e a r l y
100% eﬃcient).
The doxorubicin leakage from the liposomes after the
incorporation experiments was determined by comparing
the amount of free doxorubicin versus liposome-bound dox-
orubicin before and after the experiment. The leakage was
found to be minimal (the leakage before the incorporation
was in average 4.5% and after the reaction in average 4.2%).
2.4. Radiolabeling of Peptides. Radiolabeling of peptides
and all liposomal formulations with iodine-125 (125I) was
performed using the IODOGEN (Pierce, Rockford, IL).
The CTT2-PEG3400-DSPE peptide was labeled with 125I
using iodogen as a catalyst. 5MBq of Na125I (Amersham,
Buckinghamshire, England) in 0.5ml PBS was added to
a tube containing 10μg dried iodogen and 100μgC T T 2 -
PEG3400-DSPE peptide construct. The mixture was incu-
bated for 20min at room temperature. The 125I-bound
particle fractions were puriﬁed by elution from PD-10
columns. The activity of the peptide was determined in a
gamma counter (Cobra II, Packard Instruments).
2.5. Animal Models and Tumor Inoculation. The mice were
cared for according to the instructions of the animal facility,
and the experiments were approved by an ethical commit-
tee of Helsinki University, Finland. Male athymic nu/nu
mice (6–8weeks old, Harland) were provided with water
and maintained on regular diets ad libitum. Subcutaneous
human serous ovarian carcinoma (OV-90) xenograft models
were generated by coinjecting equal volumes of cells (∼ 5 ×
106/100μl phosphate buﬀered saline, PBS) and matrigel sub-
cutaneously into the hindlegs of nude mice. Average tumor
volumes of 65mm3–200mm3 were used for all studies.
2.6. In Vivo Biodistribution and Pharmacokinetics. Following
single i.v. tracer doses of puriﬁed 125I-CTT1-peptide
(∼40μg/mouse), 125I-CTT2-peptide (∼40μg/mouse), or
CTT2-micelles (200μg/mouse; 200kBq), the percentage
of the injected dose per gram of tissue (%ID/g) values,
corrected for radioactive decay to the time of injection,
were measured in tumor and major tissues/organs (heart,
liver, kidney, lung, muscle, brain, spleen, and tumor) by
sacriﬁcing groups of normal mice or mice bearing serous
ovarian hindleg xenografts (OV-90) at speciﬁed time points.
Additional distribution data was measured in immuno-
suppressed mice (n = 6/group) bearing subcutaneous
human mucinous ovarian tumors (A2780) using single
bolus injections of CTT2-SL liposome or Caelyx (9mg/kg,
calculated doxorubicin equivalents). Lyophilized tissue and
plasma were extracted in acid alcohol, and their doxorubicinJournal of Drug Delivery 5
Figure 3: Schematic illustration of CTT2-PEG-3400-DSPE lipo-
some [22].
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Figure 4: Hepatic accumulation of 125I-CTT2-peptides in normal
mice. Liver accumulation of peptides per gram of tissue in normal
mice (n = 5) relative to muscle (control). All values are expressed as
the percentage of the control (% control) ± SD.
concentrations were determined using a Varian spectroﬂu-
orometer. Doxorubicin ﬂuorescence intensities (a.u.) were
measured at 590nm using excitation wavelengths of 470nm,
and comparing these intensities against standard samples
containing known amounts of doxorubicin. Doxorubicin
concentrations in tumor (μg doxorubicin per gram dry
tissue) were expressed at each time point when delivered as
CTT2-SL liposome or Caelyx.
2.7. Eﬃcacy Studies
2.7.1. Doxorubicin Administered as CTT2-SL Liposomes and
Caelyx. Therapeutic eﬃcacy studies were conducted in
subcutaneous A2780 xenografts using doxorubicin, adminis-
tered as either CTT2-SL liposomes or Caelyx. Commercially
available nonliposomal (“free”) drug (i.e., doxorubicin) and
saline dilution buﬀer were used as treatment controls. A2780
ovarian cancer cells (5 × 106 in 100μl PBS) were injected
subcutaneously into the posterior ﬂanks of NMRI nude
mice (n = 40). Mice received i.v. bolus injections of
CTT2-SL liposome, Caelyx, doxorubicin, and buﬀer. CTT2-
SL liposomes were injected when tumor volumes reached
65mm3, while administration of Caelyx and doxorubicin to
diﬀerent xenograft mice was oﬀs e ti nt i m ef r o mC T T 2 - S L
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Figure 5: Tissue distribution of a single dose of 125I-CTT2-peptide
in immunosuppressed OV-90 xenograft mice. Blood and major
organs/tissues were collected at 0.5hr and 3hrs p.i. 125I-CTT2-
peptide (40μg/mouse, n = 5) and their radioactivities were
measured. Results are expressed as percentage of injected dose per
gram tissue (%ID/g). All values are given as mean ± SD.
liposomes by 3 and 6 days, respectively. Doxorubicin, CTT2-
SL liposomes, and Caelyx were injected at doses of 9mg/kg
each. Mouse body weights were monitored throughout the
study period.
Aforementioned treatments were used to collect two
independent biodistribution data sets in immunosuppressed
OV-90 xenograft mice (n = 5/group). In one set of
studies, CTT2-SL liposomes were injected using lower doses
of doxorubicin (5mg/kg) compared to Caelyx (9mg/kg).
Doxorubicin was also administered to a second group of
mice (n-3 per group) in the form of CTT2-SL-DSPE-
PEG3400 liposomes or CTT2-Caelyx-like liposomes. These
latter formulations were bolus injected using 9mg/kg (cal-
culated doxorubicin equivalents). Harvesting, weighing, and
counting of blood, tumor, and major organs in a scintillation
γ-counter were performed for all studies at speciﬁed time
points. Doxorubicin was extracted from these formulations,
and concentrations were analyzed using HPLC.
3. Results and Discussion
3.1. Biodistribution and Clearance Studies. The initial reason
to create the CTT-2 peptide was to make a peptide that was
more easily iodinated and that oﬀered a spacer that was
comfortably used for linking purposes without destroying
the bioactivity of the peptide.
In nontumor-bearing mice, greater liver accumulation of
the CTT1-peptide was observed than with the CTT2-peptide
(Figure 4). This was thought to be secondary to the increased
relative hydrophobicity of the former peptide construct. All
othertissues analyzeddemonstratednosigniﬁcant diﬀerence
in the magnitude of uptake of these peptides (data not
shown)[21].TheCTT2-peptidewasthusselectedforfurther
studies given its more rapid hepatic clearance.
In OV-90 xenograft models, substantially higher uptake
of 125I-CTT2-peptide was measured in all organs/tissues
(Figure 5), particularly in the xenograft, with tumor-to-
blood ratios ∼23 detected at 3 hrs postinjection (p.i.). This6 Journal of Drug Delivery
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coupled with the poor prognosis of this disease in humans,
showed the potential to improve treatment response using
CTT2-peptide targeted delivery, and the need to ensure
controlled and sustained drug release led us to extend this
model to investigate tumor uptake with micellar and lipo-
somal formulations (CTT2-micelles and CTT2-liposomes).
The amount of CTT2-bound peptide available for liposomal
targeting activity was found to be 500 based on the measured
average size and surface area of the resulting peptide-bound
liposomal product by dynamic light scattering and the
aforementioned reaction conditions.
For doxorubicin-containing liposomes, doxorubicin
leakage after peptide attachment was assessed by comparing
free and liposomal doxorubicin on the basis of ﬂuorometric
analysis. Leakage was found to be minimal, with leakage
before and after incorporation averaging 4.5% and 4.2%,
respectively.
Both OV-90 and mucinous ovarian carcinomas (A2780)
were thus selected as xenograft models for subsequent
nanoformulation studies. In OV-90 tumor mice, clear
targeting of CTT2-micelles was observed, reaching maxi-
mum values of 17.6% of the injected dose per gram (%ID/g)
of tumor at 6hrs p.i. (Figure 6).
Doxorubicin concentrations (μg doxorubicin per gram
dry tissue), in the form of CTT2-SL (targeted) and SL
(nontargeted Caelyx/Doxil) liposomes, were measured as
a function of time p.i. in A2780 xenografts, as shown in
Figure 7. Doxorubicin was delivered more eﬃciently and at a
faster rate to tumors using CTT2-SL liposomal formulations
compared to Caelyx, with signiﬁcantly elevated tumoral
levels of doxorubicin observed 3 days after drug injection.
CTT2-SL liposomal antitumor eﬃcacy data following i.v.
bolus injections of CTT2-SL liposome, Caelyx, doxorubicin,
and buﬀer in A2780 xenografts is shown in Figure 8.
Live mice exhibiting tumor sizes exceeding 1000mm3 were
sacriﬁced, including those at days 15 and 24 following
i.v. administration of buﬀer or doxorubicin, respectively.
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Figure 7: Comparison of doxorubicin concentrations in tumors
after a single i.v. injection of CTT2-SL liposome or Caelyx. A2780
xenografts (n = 6) were collected at 2, 6, 24, 48, 72, and 96 hours
after CTT2-liposome or Caelyx injection, and their doxorubicin
content was measured using spectrophotometry. Results are shown
as μg drug per gram of dry tissue. All values are expressed as the
mean ± SD. The diﬀerences in each time point are near signiﬁcant.
The overall diﬀerence in the AUC is signiﬁcant.
Importantly, 80% of mice treated with CTT-SL liposomes
and 50% treated with Caelyx were alive at 24 days following
initiation of treatment. Treatment with CTT2-SL liposomes
was therefore found to increase mean survival times of mice
by 38% from 27.9 to 38.6 days.
Mouse body weights were monitored throughout the
study period (Figure 9). Each doxorubicin regimen (CTT2-
SL liposome, Caelyx, and Doxorubicin) induced a slight
weight decrease with a maximum loss of about 10% at day
9. However, one week later, body weights returned to initial
levels.
Given the overall improved survival found following
treatment of A2780 xenografts with CTT2-SL liposomes,
studies were extended to assess treatment response inJournal of Drug Delivery 7
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either as CTT2-SL liposome or Caelyx. Controls were injected with
doxorubicin (9mg/kg) or saline dilution buﬀer. Injections for each
treatment group were made at day 0, day 3 and day 6, respectively.
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Figure 9: Mouse body weight changes in each treatment group
during the ﬁrst 32 days of the trial. Mice were treated with 9mg/kg
doxorubicin (calculated doxorubicin equivalents) or saline dilution
buﬀer at day 0, 3 and 6. All values are expressed as mean of 9 mice.
OV-90 xenograft models. As seen in Figure 10, despite
the lower doses of CTT2-SL liposomes administered,
eﬃcient targeting, along with rising concentrations of
doxorubicin was measured using this serous ovarian model
(Figure 10(b)) over a 6-hr time interval relative to the
untargeted formulation.
Additional serum and tumor uptake measurements con-
ducted with CTT2-SL DSPE-PEG3400 liposomes are shown
in Figure 11. Initial serum doxorubicin concentrations were
found to be lower for CTT2-SL-DSPE-PEG3400 liposomes
than for untargeted liposomes (i.e., PEG-liposomes), but the
overall kinetic proﬁle of the two liposomal formulations was
essentially equivalent over time. Figure 11(b)demonstrates
time-dependent changes in the total amount of doxorubicin
found in tumor tissue. Unlike prior studies performed with
CTT2-SL liposomes and Caelyx, where maximal diﬀerences
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Figure 10:Concentrationsofdoxorubicinin(a)serumand(b)OV-
90 xenografts in mice treated with CTT2-SLliposome and Caelyx at
0.5 and 6 hours. Data are represented as a mean of 5 mice ± SD.
in tumor tissue accumulation were detectable at 6 hours,
doxorubicin accumulations in the present study were
similar for both liposomal products at earlier time points.
However, at 16 hours p.i., a clear diﬀerence is observed
in the accumulated doxorubicin tumor concentrations,
conﬁrming earlier ﬁndings that eﬃcacy improves with
CTT2-peptide-bound liposomal delivery systems. The
extended times of accumulation may be a consequence of
the diﬀerent liposomal formulations used. Doxorubicin
concentrations, in the form of CTT2-SL-DSPE-PEG3400
liposomes, continued to rise at later time points, as against
the notable decreases in tumor concentrations observed with8 Journal of Drug Delivery
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Figure 11: Serum doxorubicin levels. Concentration of doxoru-
b i c i ni n( a )s e r u ma n d( b )O V - 9 0x e n o g r a f tm i c e( n = 3) treated
with CTT2-SL-DSPE-PEG3400. Data are represented as a mean ±
SEM.
the untargeted CTT2-Caelyx-like liposomes. Future kinetic
studies should monitor time-varying changes in tumor
doxorubicin concentrations (in the form of CTT2-peptide
targeted liposomes) at delayed time intervals (i.e., >16hrs
p.i.) in order to determine whether antitumor eﬃcacy
studies could beneﬁt from employing a dosing regimen
reﬂecting longer, sustained tumor concentrations.
4. Conclusions
Gelatinases, as extracellular targets, oﬀer a viable alternative
for tumor targeting. In gelatinase-expressing tumors, such
as OV-90, targeted liposomal constructs, 125I-CTT2-SL and
doxorubicin-containing CTT2, were found to be promising
nanotherapeutic delivery vehicles for achieving therapeutic
eﬃcacy. Table 1 summarizes the tumor uptakes of various
targeted and nontargeted liposomal formulations. Diﬀer-
ences in tumor uptake were observed range ovarian cancer
models, with the largest uptake values (i.e., ∼17% ID/g at
6hrs) achieved in OV-90 hindlimb xenografts using CTT2-
peptide-bound liposomes (∼500 peptides per liposome).
Further, CTT2-bound micelles and liposomes, as well as
the CTT2 peptide, demonstrated equivalent overall tumor
uptake values, suggesting similar bioactivity. However, to
achieve controlled and sustained drug release, we chose a
nanoformulation instead of a prodrug approach (i.e., drug-
peptide coupling). Our ﬁndings show that the utilization of
these targeted nanoformulations results in a more eﬃcient
method for delivering therapeutics than passive (i.e., non-
targeted)liposomalproducts(i.e.,Caelyx).Thedevelopment
of CTT2-peptide-bound liposomes as a clinically promising
targeting therapeutic that has the potential to improve drug
delivery to human ovarian cancers will rest on the additional
assessment of shelf and in vivo stability studies and formal
toxicity testing.
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